Effects of epidemiological structure on the transient evolution of HIV virulence

Sang Woo Park and Ben Bolker March 17, 2016

1 Introduction

How pathogen virulence evolves is a fundamental question in evolutionary biology, of great theoretical and, potentially, practical importance. While various researchers have offered critiques [CITE Ebert and Bull, Alizon and Michalakis], the trade-off theory — which postulates that parasite virulence can be explained as the long-term evolutionary outcome of a saturating relationship between parasite clearance rate and transmission rate — has also been successfully applied in several important cases [CITES?]. One particularly interesting application of these ideas is the work by Fraser et al [CITES] showing that HIV appears to satisfy the prerequisites of the tradeoff theory: in a study of discordant couples (i.e. long-term sexual partnerships with one infected and one uninfected partner), HIV virulence as measured by the rate of progression to AIDS was both heritable and covaried with the set-point viral load ([DEF]), which in turn predicted the probability of within-couple transmission. Subsequent studies [CITES] used these data to parameterize mechanistic models of HIV virulence evolution, suggesting that HIV invading a novel population would initially evolve increased virulence, peaking after approximately [XXX] years and then declining slightly to a long-stable virulence level.

The work of Shirreff et al., and particularly the predicted transient peak in HIV virulence midway through the epidemic, highlights the importance of interactions between epidemiological and evolutionary factors (Day and Proulx, 2004; Alizon, 2009). However, despite the attention to mechanistic detail at the individual or physiological level, the epidemiological structures used in these models are relatively simple. As we discuss in detail below, the existing models of HIV eco-evolutionary dynamics either use implicit models that incorporate the average effects of within-couple sexual contact — without representing the explicit dynamics of pair formation and dissolution or accounting for extrapartnership contact — or use an agent-based formulation with parameters that effectively lead to random mixing among infected and uninfected individuals. Here we explore the effects of incorporating *explicit* epidemiological structure in eco-evolutionary models.

We add complexity to the epidemiological model following the general approach of Champredon et al. (2013); individuals join and leave partnerships at a specified rate, and can have sexual contact both within and outside of established partnerships. At the same time, our analysis somewhat simplifies the models of Shirreff et al., for computational tractability; we check that our qualitative results are not sensitive to these simplifications. In order to explore how virulence evolution depends on epidemiological structure, we consider a series of models with increasing levels of complexity. In order to avoid dependence of the results on a particular set of parameters — as we explain below, finding matching sets of parameters across models with widely differing epidemiological structures is challenging — we evaluate our models across a wide range of parameters, again following Champredon et al. in using a Latin hypercube design. For each model run, we compute a set of metrics (peak virulence, timing of virulence peak, equilibrium virulence) that summarize the evolutionary trajectory of a simulated HIV epidemic.

2 Methods

2.1 Model formulation

As our primary goal is to explore how different epidemiological structures (i.e. partnership dynamics and contact structures) affect our conclusions about the evolution of virulence, our models use a simplified description of within-host dynamics and heritability derived from Shirreff et al.'s multi-strain evolutionary model. Like Shirreff et al., we focus on the evolution of mean \log_{10} set-point viral load, SPVL (which we denote as α), rather than virulence (i.e. rate of progression to AIDS) itself. Instead of accounting for progression through the three main stages of HIV infection (primary, asymptomatic, and disease), we use a single-stage disease model, with a simple exponentially distributed infectious period instead of the Weibull-distributed infectiousness which Shirreff et al. (and many other HIV models) use. However, we do account for varying transmission rates and durations of each disease stage by summing the durations of three stages (again based on Shirreff et al.'s model) and taking the duration-weighted average of transmission rates of three stages. Thus the within-couple transmission rate, β , for our models is given by:

$$\beta(\alpha) = \frac{D_P \beta_P + D_A(\alpha) \beta_A(\alpha) + D_D \beta_D}{D_P + D_A(\alpha) + D_D}$$
(1)

where the duration of infection (D_P and D_D) and rate of transmission (β_P and β_D) of the Primary and Disease stages of infection are independent of the host's SPVL. Following Shirreff et al., the duration of infection (D_A) and rate of transmission (β_A) for the Asymptomatic stage are Hill functions of the SPVL:

$$D_{A}(\alpha) = \frac{D_{\text{max}} D_{50}^{D_{k}}}{V_{\alpha}^{D_{k}} + D_{50}^{D_{k}}},$$

$$\beta_{A}(\alpha) = \frac{\beta_{\text{max}} V_{\alpha}^{\beta_{k}}}{V_{\alpha}^{\beta_{k}} + \beta_{50}^{\beta_{k}}},$$
(2)

where $V_{\alpha}=10^{\alpha}$. The uncoupled and extra-couple transmission rates are scaled by multiplying the within-couple transmission rate β by the contact ratios c_u/c_w and c_e/c_w .

Like Shirreff et al. but unlike Champredon et al., we simplify the evolutionary model by using a one-to-one genotype-phenotype mapping (i.e. a single strain can only produce a single SPVL). Unlike Champredon et al. but like Shirreff et al., we also use a simple susceptible-infected-susceptible formulation; rather than modeling birth and death (or more specifically, recruitment into the sexually active population and death), we assume that whenever an individual dies from infection, another enters the susceptible compartment.

We developed six multi-strain evolutionary models, each of which is based on different assumptions regarding partnership dynamics. Specifically, we focus on the effect of instantaneous partnership formation and extra couple mixing on the evolution of mean \log_{10} SPVL.

The first four models consider explicit partnership dynamics and are based on Champredon et al's model. Model 1 and 2 assume non-instantaneous partnership formation and consist of five states that are classified by infection status and partnership status. S is the number of single susceptible individuals, and I is the number of single infected individuals. SS is the number of susceptible-susceptible couples, SI is the number of serodiscordant couples, and II is the number of concordant positive couple. Model 1 includes extra couple mixing and uncoupled mixing whereas model 2 only considers within-couple transmission. Model 3 and 4 assume instantaneous partnership formation and consist of 3 states: SS, SI, and II. Like model 1 and 2, model 3 includes extra couple mixing and model 4 only considers within-couple transmission.

In contrast, models 5 and 6 are not explicitly structured. Model 5 is an implicit serial monogamy model based on Shirreff et al.'s model. It is actually a random mixing model that consist of only two states, S and I, and does not consider explicit partnership dynamics. However, to simulate the effect instantaneous partnership formation, it uses adjusted transmission rate that is derived from approximated basic reproduction number of a serial monogamy model. Finally, model 6 is a simple random-mixing model.

The mutational process in our model is directly taken from Shirreff et al.. Over the course of infection, mutation occurs within the host. However, it is assumed that SPVL of an infected individual is determined by the SPVL at the time of infection for simplicity (and is not further affected by withinhost mutation). Instead, the mutational effect takes place when an infected individual transmits the virus to a susceptible individual. First, the distribution of \log_{10} SPVL is discretized into a vector:

$$\alpha_i = (\alpha_{max} - \alpha_{min}) \frac{(i-1)}{n-1} + \alpha_{min} \qquad i = 1, 2, 3, \dots n.$$
 (3)

Then, we construct a mutational matrix, M — which is multiplied with the transmission term — so that M_{ij} is the probability that a newly infected individual will have \log_{10} SPVL of j given that the infector has \log_{10} of i. Finally, the probabilities are normalized so that each row sums to 1:

$$M_{ij} = \frac{\Phi(\alpha_j + d/2) - \Phi(\alpha_j - d/2)}{\Phi(\alpha_{max} + d/2) - \Phi(\alpha_{min} - d/2)},$$
(4)

where $\Phi(j)$ is the Gaussian cumulative distribution function with mean α_i and variance of σ_M^2 , and $d=(\alpha_{\max}-\alpha_{\min})/n$. Transmission rate and disease induced mortality rates are discretized into a vector as well:

$$\beta_i = \beta(\alpha_i)$$

$$\lambda_i = \frac{1}{D_P + D_A(\alpha_i) + D_D}$$
(5)

2.2 Latin Hypercube Sampling - we should probably explain model parameters before this...?

Not only is there discrepancy in parameters regarding partnership dynamics between sources, but it is also difficult to determine the exact value due to many reasons. Furthermore, recent studies suggest that the previously measured transmission rate of the acute phase was over-estimated. Thus, we want to allow for uncertainties in model parameters and perform Latin hyper cube sampling on the following parameters: β_P , D_P , β_D , D_D , ρ , c, c_u/c_w , and c_e/c_w . Each parameter is divided We do not allow for uncertainties in parameters that are directly related to evolutionary process.

2.3 Simulation runs

One of the most difficult parts of our model comparison exercise is coming up with sets of parameters that are commensurate against many different model structures. For the most part, our models are too complex to easily derive analytical correspondences among them. Given a numerical criterion, such as r (initial exponential growth rate) or \mathcal{R}_0 (intrinsic reproductive number), we can adjust one or more parameters by brute force to ensure that all of the models match according to that criterion. While \mathcal{R}_0 is often considered the most fundamental property of an epidemic, and might thus seem to be a natural goal, here we focus on matching the initial growth rate r for several reasons. First, our primary interest is in the transient evolutionary dynamics of virulence, which are more strongly affected by r than \mathcal{R}_0 (CITE?). Second, r is in general more directly observable in real epidemics; r can be estimated by simply fitting an exponential curve to the initial incidence or prevalence curves (CITE Ma et al.),

refer to Table 1 and describe where the new parameters come from; e.g. decisions we made about new scaling parameters while \mathcal{R}_0 typically requires either (1) knowledge of *all* epidemic parameters or (2) relatively sophisticated back-calculation based on r and knowledge of the serial interval or generation interval of the disease (CITE Wallinga, Teunis, Lipsitch, etc.) Thus, we scale a parameter so that every run has an equal exponential rate of growth rate.

In order to allow for all models to have equal initial exponential growth rate, r, we need to pick a parameter, s, so that $\lim_{s\to 0} r(s) = 0$ and $\lim_{s\to \infty} r(s) = \infty$. As adjusting either partnership change rate (i.e. partnership formation and dissolution rate) or transmission rate does not fulfill this requirement for certain models, we decided to scale partnership change rate and dissolution rate by the same factor of γ : $beta_{\rm adj} = \gamma \beta_{\rm base}$, $c_{\rm adj} = \gamma c_{\rm base}$, $\rho_{\rm adj} = \gamma \rho_{\rm base}$. Since transmission rate is adjusted by the scale of γ , uncoupled and extra-couple transmission rates are adjusted as well. For model 3, 4, and 5, all of which assume instantaneous partnership, only the transmission rate and partnership dissolution rate are adjusted.

We run each model for 1000 times with different parameter sets calculated from latin hypercube sampling with fixed starting condition: mean \log_{10} SPVL of 3 and epidemic size of 10^{-4} (refer to appendix). After each run, initial exponential growth rate is calculate. Then, paraeters are scaled so that the initial exponential growth rate is scaled to 0.04, which is approximately equal to that of Shirreff et al's model.

For each model we derive the following summary statistics:

mention that baseline parameters are geometric means of ranges

define each summary statistic and explain what it tells us

peak time ...

peak time ...
peak virulence ...
relative peak virulence ...

equilibrium virulence ...

3 Results

Our simplifications of Shirreff et al.'s model reproduce the qualitative behaviour reasonably well; as r decreases from 0.084 to 0.42 the initial trajectory of increasing virulence brackets the rate from the original model (Figure 1a). Our model produces lower peak virulence (\approx ? vs. \approx ?) and equilibrium virulence \approx ? vs. \approx ?) than Shirreff's, probably because Changing the initial infectious density (I(0)), while it produces the expected changes in the initial epidemic trajectory (Supplementary material), has little effect on the virulence trajectory, making the virulence peaks slightly later and larger as I(0) decreases and allows a longer epidemic phase before the transition to endemic dynamics (Figure 1b). Decreasing the initial virulence similarly but more strongly leads to progressively later, larger peaks in virulence.

describe more; is this because we can't match both R0 and r? Can we match r exactly?




Figure 1: Baseline dynamics. Time series of mean population virulence (\log_{10} SPVL). (a) Shirreff model, effects of varying r. (b) Effects of varying initial infectious density I(0). (c) Effects of varying initial mean virulence $\alpha(0)$




Figure 2: Envelopes of virulence trajectories under all models




Figure 3: Univariate distributions of summary statistics. Note: point for eqvir/random is a placeholder, will have to be explained

For the baseline set of parameters, with the initial epidemic spread rate scaled to be the

Figure to-do:

• fig 1. tweak size? remove redundant y axes/labels?

- fig 3. add random-mixing model; remove x-axis label; rename factor to make strip labels prettier
- fig 4. re-order (reverse legend order), figure out how to tweak random density width
- Univariate plots
- Bivariate plots
- · Unscaled sensitivity

4 Discussion

5 To do

- clean up code and results
- incorporate pictures

just double-checking: Figure 1 shows results from the implicit model, right?

- finish writing!
- hard parts of the results
 - explaining similarities among the models: why does implicit look most like pair formation model? (see R0comparison HTML)
 - explaining sensitivity plot

See Bolker JRSI Google scholar cites (alternative link)

A Model details

Since we use multi-strain models, in which the distribution of \log_{10} SPVL has been discretized into a vector, we use a matrix notation to describe our models. Five states described in the method section is replaced with the following notations: S, I_i , SS, SI_i , II_{ij} . Subscript indicates a strain that an individual is infected with. For example, I_i is number of infected individuals with \log_{10} SPVL of α_i , and II_{ij} is the number of concordant couples, in which two partners have \log_{10} SPVL of α_i and α_j . II_{ij} is equivalent to II_{ji} . Lastly, we define Kronecker delta as follows:

$$\delta_{ij} = \begin{cases} 0 & \text{if} \quad i \neq j, \\ 1 & \text{if} \quad i = j. \end{cases}$$
 (6)

explain non-standard use of Kronecker delta as expo-

nent!

Model 1 and 2 - Partnership dynamic

Single individuals acquire partners at rate ρ : $S' = -\rho S$ and $I'_i = -\rho I_i$. We follow Champredon et al's results and assume that single individuals are distributed into couple states through binomial distribution:

$$SS' = \frac{\rho S \cdot S}{2(S + \sum_{k} I_{k})}$$

$$SI'_{i} = \frac{\rho S \cdot I_{i}}{S + \sum_{k} I_{k}}$$

$$II'_{ij} = (\frac{1}{2})^{\delta_{ij}} \cdot \frac{\rho I_{i} \cdot I_{j}}{S + \sum_{k} I_{k}}$$
(7)

We introduce Kronecker delta above to differentiate the partnership formation rate for II_{ij} when i=j from that of $I\neq j$. When i=j — like the partnership formation rate of SS — partnership formation rate becomes $II'_{ii}=\frac{\rho I_i \cdot I_i}{2(S+\sum_k I_k)}$ due to binomial distribution. On the other hand, when $i\neq j$, partnership formation rate becomes $II'_{ij}=\frac{\rho I_i I_j}{S+\sum_k I_k}$. Partnerships dissolve at rate c: SS'=-cSS, $SI'_i=-cSI_i$, and $II_{ij}=-cSI_i$.

Partnerships dissolve at rate \overline{c} : SS' = -cSS, $SI'_i = -cSI_i$, and $II_{ij} = -cII_{ij}$. Unlike single strain model, where both individuals leaving the II partnership would enter I, we have to account for strains which the individuals

in concordant partnership are infected with (i.e. both partners in II_{ii} enter I_i whereas only one partner in II_{ij} enter I_i).

$$S' = 2cSS + \sum_{k} cSI_{k}$$

$$I'_{i} = cSI_{i} + \sum_{k} 2^{\delta_{ik}} cII_{ik}$$
(8)

Combining partnership formation and dissolution process yields the following equation:

$$S' = -\rho S + 2cSS + \sum_{k} cSI_{k}$$

$$I'_{i} = -\rho I_{i} + cSI_{i} + \sum_{k} 2^{\delta_{ik}} cII_{ik}$$

$$SS' = \frac{\rho S \cdot S}{2(S + \sum_{k} I_{k})} - cSS$$

$$SI'_{i} = \frac{\rho S \cdot I_{i}}{S + \sum_{k} I_{k}} - cSI_{i}$$

$$II'_{ij} = (\frac{1}{2})^{\delta_{ij}} \cdot \frac{\rho I_{i} \cdot I_{j}}{S + \sum_{k} I_{k}} - cII_{ij}$$

$$(9)$$

Model 1 and 2 - Infection

Within-couple transmission occurs in both models. An infected partner in SI partnership transmits virus to a susceptible partner, and partnership state becomes $II: SI'_i = -\beta_i SI_i$. Since we assume that mutation occurs, II_{ij} , where $i \neq j$, can be formed from both SI_i and SI_j partnership: $II'_{ij} = M_{ij}\beta_i SI_i + M_{ji}\beta_j SI_j$. On the other hand, II_{ii} can only be formed from an SI_i partnership: $II'_{ii} = M_{ii}\beta_i SI_i$. Using the Kronecker delta notation, we obtain following set of equations that describe within-couple transmission dynamics:

$$SI_i' = -\beta_i SI_i$$

$$II_{ij} = (\frac{1}{2})^{\delta_{ij}} \cdot (M_{ij}\beta_i SI_i + M_{ji}\beta_j SI_j)$$
(10)

Champredon et al define the proportion of infectious extra-couple and uncoupled contact through the following term:

$$P = \frac{c_u I + c_e (SI + 2II)}{c_u (S + I) + 2c_e (SS + SI + II)}.$$
 (11)

Effective uncoupled, c_u , and extra couple, c_e , contact rate can be divided into two terms: uncoupled/extra-couple contact rate \times rate of transmission per contact. Therefore, transmission rate per contact term in c_u and c_e is canceled out in the equation above. Using this property, we modify the equation above as follows:

$$P = \frac{r_u I + r_e (SI + 2II)}{r_u (S + I) + 2r_e (SS + SI + II)},$$
(12)

where $r_u=c_u/c_w$ and $r_e=c_e/c_w$ are the relative uncoupled/extra-couple contact rates. This simplification is useful in a multi-strain model since we cannot multiply a vector with a single value (e.g. c_uS in denominator) if we use Champredon et al's equation as it is. Extending the above equation to multi-strain model so that P_i represents the proportion of the extra-couple and uncoupled contact of an infected individual with strain i, we obtain the following equation:

$$P_{i} = \frac{r_{u}I_{i} + r_{e}(SI_{i} + \sum_{k}(II_{ik} + \delta_{ik}II_{ik}))}{r_{u}(S + \sum_{k}I_{k}) + r_{e}(2SS + \sum_{k}2SI_{k} + \sum_{l}\sum_{k}(1 + \delta_{lk})II_{lk})},$$
 (13)

Using the equation above, we can model uncoupled and extra-couple mixing. For convenience, uncoupled and extra-couple transmission rates, c_u and c_e , will be replaced with $U_i = r_u \beta_i$ and $E_i = r_e \beta_i$ from now on.

Single susceptible individuals become infected and enter single infected compartment at the total rate of $\sum_k P_k U_k S$. Through mutation, newly infected individuals are distributed into each single infected compartments with different strains: $I_i' = \sum_k M_{ki} P_k U_k S$. Either partners in SS partnership can be infected and the partnership state can become SI partnership at the total rate of $\sum_i 2P_i E_i SS$. Formation of SI_i partnership is similar to the process through which single susceptible individuals are distributed into single infected compartments: $SI_i' = \sum_k 2M_{ki}P_kE_kSS$. Lastly, susceptible partner of an SI partnership can be infected due to uncoupled/extra-couple contacts and partnership can move to an II partnership. Like previous cases, SI_i partnership moves out of the compartment at a rate of $\sum_k P_k E_k SI_i$. Mutation process is similar to that of within-couple transmission. The only difference is that the $\log_1 0$ SPVL of a newly infected partner is not determined by its original partner but from an extra couple partner (i.e. the term P_i): $II_{ij}' = (1 - \frac{\delta_{ij}}{2})(\sum_k (M_{kj}P_kE_kSI_i + M_{ki}P_kE_kSI_j))$. Combining these equations we get the following set of equations that describe all the transmission dynamics

Model 1 and 2 - Disease induced mortality

Disease induced death rate, λ , is given by taking the reciprocate of the total duration of the infection: $\lambda_i = 1/(D_A + D_P(\alpha_i) + D_D)$. Since we assume SIS formulation, where infected individuals that die from infection enter single susceptible compartment, we obtain the following equation for the single infected individuals:

$$S' = \sum_{k} \lambda_k I_k$$

$$I_i = -\lambda_i I_i$$
(14)

If an infected individual in a partnership dies, partnership dissolves. Thus, an SI_i partnership dissolves at a rate $-\lambda_i$, and the susceptible partner enters single susceptible compartment at rate $\lambda_i SI_i$ (infected partner that dies enter single susceptible compartment at an equal rate as well due to SIS formation):

$$S' = \sum_{k} 2\lambda_k SI_k$$

$$SI_i = -\lambda_i SI_i$$
(15)

Similarly, II_{ij} partnership dissolves at a rate $-(\lambda_i + \lambda_j)$, but two cases, when $i \neq j$ and i = j, must be considered separately. When an II_{ij} partnership dissolves due to disease induced mortality, where $i \neq j$, death of partner with strain i causes its partner to enter I_j compartment at rate $\lambda_j II_{ij}$, and vice versa. When an II_ii partnership dissolves, death of either partner causes the other partner to enter I_i compartment at rate $\lambda_i II_{ii}$, which sums up to $2\lambda_i II_{ii}$. Combining these dynamics yield the following equation:

$$S' = \sum_{l} \sum_{k} 2^{\delta_{lk}} \lambda_{k} II_{lk}$$

$$I'_{i} = \sum_{k} 2^{\delta_{ik}} \lambda_{k} II_{ik}$$

$$II'_{ij} = -(\lambda_{i} + \lambda_{j}) II_{ij}$$

$$(16)$$

Finally, combining all these equations give us the full model, which is model 1. We can simply take out the uncoupled and extra couple transmission term to obtain equation 2:

$$S' = -\rho S + 2cSS + \sum_{k} cSI_{k} - \sum_{k} P_{k}U_{k}S + \sum_{k} \lambda_{k}I_{k}$$

$$+ \sum_{k} 2\lambda_{k}SI_{k} + \sum_{l} \sum_{k} 2^{\delta_{lk}}\lambda_{k}II_{lk}$$

$$I'_{i} = -\rho I_{i} + cSI_{i} + \sum_{k} 2^{\delta_{ik}}cII_{ik} + \sum_{k} M_{ki}P_{k}U_{k}S - \lambda_{i}I_{i}$$

$$+ \sum_{k} 2^{\delta_{ik}}\lambda_{k}II_{ik}$$

$$SS' = \frac{\rho S \cdot S}{2(S + \sum_{k} I_{k})} - cSS - \sum_{i} 2P_{i}E_{i}SS$$

$$SI'_{i} = \frac{\rho S \cdot I_{i}}{S + \sum_{k} I_{k}} - cSI_{i} - \beta_{i}SI_{i} + \sum_{k} 2M_{ki}P_{k}E_{k}SS - \sum_{k} P_{k}E_{k}SI_{i}$$

$$- \lambda_{i}SI_{i}$$

$$II'_{ij} = (\frac{1}{2})^{\delta_{ij}} \cdot \frac{\rho I_{i} \cdot I_{j}}{(S + \sum_{k} I_{k})} - cII_{ij} + (\frac{1}{2})^{\delta_{ij}} \cdot (M_{ij}\beta_{i}SI_{i} + M_{ji}\beta_{j}SI_{j})$$

$$+ (\frac{1}{2})^{\delta_{ij}} \cdot (\sum_{k} (M_{kj}P_{k}E_{k}SI_{i} + M_{ki}P_{k}E_{k}SI_{j})) - (\lambda_{i} + \lambda_{j})II_{ij}$$

Model 3 and 4 - Partnership dynamic

Since model 3 and 4 assume instantaneous partnership formation, there are only three states: SS, SI_i , and II_{ij} . Partnership dissolution is equal to that of model 1 and 2: SS' = -cSS, $SI'_i = -cSI_i$, and $II'_{ij} = -II_{ij}$. Once the individuals leave partnership, they enter temporary compartments and are distributed into a partnership through binomial distribution:

$$X = 2cSS + \sum_{k} cSI_{k}$$

$$Y_{i} = cSI_{i} + \sum_{k} 2^{\delta_{ik}} cII_{ik}$$

$$SS' = -cSS + \frac{X^{2}}{2(X + \sum_{k} Y_{k})}$$

$$SI'_{i} = -cSI_{i} + \frac{XY_{i}}{X + \sum_{k} Y_{k}}$$

$$II'_{ij} = -cII_{ij} + (\frac{1}{2})^{\delta_{ij}} \frac{Y_{i}Y_{j}}{X + \sum_{k} Y_{k}}.$$
(18)

Model 3 and 4 - Infection

Model 3 and 4 share the within-couple transmission term with model 1 and 2. Since there is no single state, only extra couple transmission exists:

$$P_{i} = \frac{r_{e}(SI_{i} + \sum_{k}(II_{ik} + \delta_{ik}II_{ik}))}{r_{e}(2SS + \sum_{k}2SI_{k} + \sum_{l}\sum_{k}(II_{lk} + \delta_{kl}II_{lk}))}.$$
 (19)

Movement from SS state to SI state and SI to SS is modeled through the same equation that is used in model 1 and 2.

Model 3 and 4 - Disease induced mortality

Disease induced mortality is modeled similar to model 1 and 2. However, as single state does not exist in model 3 and 4, individuals that has left their partnerships due to death of their partners enter temporary compartments and form partners instantly:

$$X = \sum_{k} 2\lambda_{k} S I_{k} + \sum_{l} \sum_{k} 2^{\delta_{lk}} \lambda_{k} I I_{lk}$$

$$Y_{i} = \sum_{k} 2^{\delta_{ik}} \lambda_{k} I I_{ik}$$

$$SS = \frac{X^{2}}{2(X + \sum_{k} Y_{k})}$$

$$SI_{i} = -\lambda_{i} S I_{i} + \frac{X Y_{i}}{X + \sum_{k} Y_{k}}$$

$$II'_{ij} = -(\lambda_{i} + \lambda_{j}) I I_{ij} + (\frac{1}{2})^{\delta_{ij}} \cdot \frac{Y_{i} Y_{j}}{X + \sum_{k} Y_{k}}$$

$$(20)$$

Combining all these dynamics, we have equation 3. If we remove extracouple transmission, we have equation 4.

$$X = 2cSS + \sum_{k} cSI_{k} + \sum_{k} 2\lambda_{k}SI_{k} + \sum_{l} \sum_{k} 2^{\delta_{lk}}\lambda_{k}II_{lk}$$

$$Y_{i} = cSI_{i} + \sum_{k} 2^{\delta_{ik}}cII_{ik} + \sum_{k} 2^{\delta_{ik}}\lambda_{k}II_{ik}$$

$$SS = -cSS + \frac{X^{2}}{2(X + \sum_{k} Y_{k})} - \sum_{i} 2P_{i}E_{i}SS$$

$$SI_{i} = -cSI_{i} + \frac{XY_{i}}{X + \sum_{k} Y_{k}} - \beta_{i}SI_{i} + \sum_{k} 2M_{ki}P_{k}E_{k}SS$$

$$- \sum_{k} P_{k}E_{k}SI_{i} - \lambda_{i}SI_{i}$$

$$II_{ij} - cII_{ij} + (\frac{1}{2})^{\delta_{ij}} \frac{Y_{i}Y_{j}}{X + \sum_{k} Y_{k}} + (\frac{1}{2})^{\delta_{ij}} \cdot (M_{ij}\beta_{i}SI_{i} + M_{ji}\beta_{j}SI_{j})$$

$$+ (\frac{1}{2})^{\delta_{ij}} \cdot (\sum_{k} (M_{kj}P_{k}E_{k}SI_{i} + M_{ki}P_{k}E_{k}SI_{j})) - (\lambda_{i} + \lambda_{j})II_{ij}$$

Model 5

Model 5 is an implicit instantaneous partnership formation model, which uses adjusted transmission rate, β' , that is derived from Hollingsworth et al's approximated basic reproduction number:

$$\beta_i' = \frac{c\beta_i}{c + \beta_i + \lambda_i}. (22)$$

Thus, we get the following model:

$$S' = \sum_{k} \lambda_k I_k - \sum_{k} \beta_k' S I_k$$

$$I_i = \sum_{k} M_{ki} \beta_k' S I_k - \lambda_i I_i$$
(23)

Initial distribution of infected individuals

We follow Champredon et al's result to calculate the initial distribution of infected individuals. For model 1 and 2, we have disease equilibrium state of $S^* = \frac{c}{c+\rho}$ and $SS^* = \frac{1-S^*}{2}$. We let $\epsilon = 10^{-4}$, which is the total number of infected individuals in the beginning of simulation and D be the vector such that D_i represent the proportion of individuals with \log_{10} SPVL of i. Y_i is taken from normal distribution with mean 3 and is normalized so that $\sum_i D_i = 1$. Then, we have the following initial distribution of each states:

$$S(0) = (1 - \epsilon)S^*$$

$$SS(0) = (1 - \epsilon)^2 SS^*$$

$$SI_i(0) = 2\epsilon (1 - \epsilon)SS^*D_i$$

$$I_i(0) = \epsilon S^*D_i$$

$$II_{ij}(0) = (\frac{1}{2})^{\delta_{ij}} 2\epsilon^2 SS^*D_i D_j.$$
(24)

Since model 3 and 4 do not have single state, $SS^*=1$ at the disease free equilibrium and the initial distribution becomes as follows:

$$SS(0) = (1 - \epsilon)^{2} SS^{*}$$

$$SI_{i}(0) = 2\epsilon (1 - \epsilon) SS^{*} D_{i}$$

$$II_{ij}(0) = (\frac{1}{2})^{\delta_{ij}} 2\epsilon^{2} SS^{*} D_{i} D_{j}.$$
(25)

Lastly, as model 5 is an implicit model, which does not consider different stages of partnership, we have the following initial distribution.

$$S(0) = 1 - \epsilon$$

$$I_i(0) = \epsilon D_i.$$
(26)

References

Alizon, S. (2009, May). The Price equation framework to study disease within-host evolution. *Journal of Evolutionary Biology* 22(5), 1123–1132.

Champredon, D., S. Bellan, and J. Dushoff (2013, 12). Hiv sexual transmission is predominantly driven by single individuals rather than discordant couples: A model-based approach. *PLoS ONE 8*(12), e82906.

- Day, T. and S. R. Proulx (2004, April). A General Theory for the Evolutionary Dynamics of Virulence. *The American Naturalist* 163(4), E40–E63.
- Hollingsworth, T., R. Anderson, and C. Fraser (2008, September). HIV-1 Transmission, by Stage of Infection. *Journal of Infectious Diseases* 198(5), 687–693.
- Shirreff, G., L. Pellis, O. Laeyendecker, and C. Fraser (2011, October). Transmission selects for HIV-1 strains of intermediate virulence: A modelling approach. *PLoS Computational Biology* 7(10), e1002185. WOS:000297262700019.

Table 1: Parameter ranges/values

| Table 1: Parameter ranges/values | | | |
|----------------------------------|------------------------------------|---------------|-----------------------------|
| Notation | Description | Range/Value | Source |
| ρ | Partnership formation rate | 1/10-2/5 | Champredon et al. (2013) |
| c | Partnership dissolution rate | 1/15-1/5 | Champredon et al. (2013) |
| c_u/c_w | Relative contact rate uncoupled | 1/5-5 | Assumption |
| c_e/c_w | Relative contact rate extra- | 0.01-1 | Champredon et al. (2013) |
| | couple | | |
| eta_P | Rate of transmission during pri- | 1.31-5.09 | Hollingsworth et al. (2008) |
| | mary infection | | |
| eta_D | Rate of transmission during high | 0.413-1.28 | Hollingsworth et al. (2008) |
| | transmission disease stage | | |
| D_P | Duration of primary infection | 1.23/12-6/12 | Hollingsworth et al. (2008) |
| D_D | Duration of high transmission | 4.81/12-14/12 | Hollingsworth et al. (2008) |
| | disease stage | | |
| β_{max} | Maximum rate of transmission | 0.317 | Shirreff et al. (2011) |
| | during asymptomatic stage | | |
| eta_{50} | SPVL at which infectiousness is | 13938 | Shirreff et al. (2011) |
| | half maximum | | |
| $eta_{m{k}}$ | Hill coefficient: steepness of | 1.02 | Shirreff et al. (2011) |
| | increase in infectiousness as a | | |
| | function of SPVL | | |
| D_{max} | Duration of primary infection | 25.4 | Shirreff et al. (2011) |
| D_{50} | SPVL at which duration of | 3058 | Shirreff et al. (2011) |
| | asymptomatic infection is half | | |
| | maximum | | |
| D_k | Hill coefficient: steepness of de- | 0.41 | Shirreff et al. (2011) |
| | crease in duration as a function | | |
| | of SPVL | | |
| σ_{M} | Mutation standard deviation of | 0.12 | Shirreff et al. (2011) |
| | $\log_{10} {	ext{SPVL}}$ | | |
| α_{min} | Minimum $\log_{10} \text{SPVL}$ | 2 | Shirreff et al. (2011) |
| α_{max} | Maximum \log_{10} SPVL | 2 | Shirreff et al. (2011) |
| n | Number of strains | 21 | Assumption |